47 results on '"Estabrook, Joseph"'
Search Results
2. Selective enrichment of plasma cell-free messenger RNA in cancer-associated extracellular vesicles
3. An expanded universe of cancer targets
4. Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors
5. PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia
6. An expanded universe of cancer targets
7. Supplementary Table 5 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
8. Supplementary Table 4 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
9. Supplementary Table 9 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
10. Supplementary Table 2 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
11. Supplementary Fig. 11 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
12. Supplementary Table 7 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
13. Supplementary Table 11 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
14. Supplementary Fig. 3 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
15. Supplementary Fig. 6 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
16. Data from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
17. Supplementary Fig. 5 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
18. Supplementary Table 6 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
19. Supplementary Fig. 7 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
20. Supplementary Table 8 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
21. Supplementary Fig. 4 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
22. Supplementary Materials and Methods from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
23. Supplementary Table 3 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
24. Supplementary Fig. 2 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
25. Supplementary Fig. 9 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
26. Supplementary Fig. 8 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
27. Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
28. Predicting transcription factor activity using prior biological information
29. Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors
30. Chronic IL1β Exposure Enhances Self-Renewal Ability and Myeloid Priming in TET2 Deficient Stem and Progenitor Cells
31. Selective enrichment of plasma cell-free messenger RNA in cancer-associated extracellular vesicles
32. An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer
33. Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
34. PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia
35. 3024 – GERMLINE RUNX1 MUTATIONS -MEDIATED CHANGES COOPERATES WITH INFLAMMATORY MICROENVIRONMENT TO DRIVE DEFECTIVE HEMATOPOIESIS IN FAMILIAL PLATELET DISORDER
36. Abstract 1133: Combined inhibition of cKIT and Lysine-Specific Demethylase 1 as a therapeutic strategy in acute myeloid leukemia
37. Interplay between Inflammatory Microenvironment and RUNX1-Mediated Transcriptomic Changes Drives Defective Hematopoiesis in Familial Platelet Disorder
38. Asxl1deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors
39. An Omic and Multidimensional Spatial Atlas from Serial Biopsies of an Evolving Metastatic Breast Cancer
40. Oncogenic SETBP1 Mutations Combine with Activating Mutations in CSF3R to Produce a Highly Proliferative, Lethal Leukemia through Aberrant Myc Signaling
41. ASXL1 Directs Neutrophilic Differentiation via Modulation of MYC and RNA Polymerase II
42. Transcriptome alterations in myotonic dystrophy skeletal muscle and heart
43. Antisense transcription of the myotonic dystrophy locus yields low-abundant RNAs with and without (CAG)n repeat
44. Transcriptome alterations in myotonic dystrophy skeletal muscle and heart.
45. A response to 'The Chaplain's Dilemma'
46. Abraham the passenger his privilege and duty described in an election-sermon at Boston N.E. May 30. 1705. / By Joseph Easterbrooks [i.e., Esterbrook] A.M. and Pastor of the Church of Christ at Concord. ; [Seven lines of quotations]
47. Crossing the Border: International Issues That Affect IP Litigation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.